In a panel discussion at ACR Convergence 2025, three experts provided insight into how mentorship, personal values and more helped them develop the skills and habits necessary to become a master clinician.
Fibrinogen-like protein-1 (FGL-1) may play a key role in the onset of autoimmunity by suppressing T cell activation in primary Sjögren disease, according to findings from Otsuka et al. Their study, which examined the influence of interorgan communication on disease pathogenesis in mice models and patients with primary Sjögren disease, may help facilitate novel diagnostic or therapeutic strategies targeting immune checkpoint molecules in autoimmune diseases.
ACR Convergence 2025 speakers reviewed new fibromyalgia insights, from the first new drug approval since 2009 to nociplastic pain concepts & cognitive behavioral therapy.
The Review Course at ACR Convergence 2025 provided a comprehensive update for practitioners. Highlights from the sections on cutaneous manifestations of rheumatic diseases, gout, macrophage activation syndrome and vasculitis.
ACR Convergence 2025 experts explore gout’s deep ties to MetS, insulin resistance and cardiovascular mortality, weighing new data on colchicine, febuxostat and SGLT2 inhibitors.
The Review Course at ACR Convergence 2025 provided a comprehensive update for practitioners. Highlights from the sections on SLE and lupus nephritis, inflammatory brain diseases, drug management of rheumatic diseases and mimics of inflammatory myopathies.
The FDA as approved the biosimilar treatments denosumab-nxxp (Bildyos) and denosumab-nxxp (Bilprevda) for all indications of denosumab, their reference product, including osteoporosis in postmenopausal women.
Starting Nov. 13, the long-running ACR@Work newsletter is transforming into The Rheum Advocate, delivering the latest updates on advocacy, policy developments, clinical practice support and the issues that matter most to rheumatology professionals.
The ACR’s resolutions at the Interim HOD meeting, held Nov. 14–18, will address non-compete agreements as well as the use of artificial intelligence (AI) in prior authorization processes.